PMID- 29172822
OWN - NLM
STAT- MEDLINE
DCOM- 20190315
LR  - 20190315
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 30
IP  - 1
DP  - 2019
TI  - Antithrombotic efficacy of bivalirudin compared to unfractionated heparin during 
      percutaneous coronary intervention for acute coronary syndrome.
PG  - 105-111
LID - 10.1080/09537104.2017.1384541 [doi]
AB  - Bivalirudin is associated with an increased risk of acute stent thrombosis (AST) 
      compared to unfractionated heparin (UFH) in acute coronary syndrome patients 
      (ACS) during short-duration percutaneous coronary intervention (PCI). The 
      mechanisms involved are unknown. We aimed to investigate the antithrombotic 
      efficacy of bivalirudin compared to UFH during PCI. In a monocenter study, we 
      prospectively enrolled 30 patients undergoing PCI for a non-ST elevation ACS. 
      They were randomly assigned to a single intravenous (IV) bolus of UFH (70 IU/kg) 
      or an IV bolus of bivalirudin 0.75 mg/kg followed by a 1.75 mg/kg/h infusion 
      during PCI. All patients received a loading dose (LD) of 180 mg of ticagrelor at 
      the time of PCI. The VASP index and activated partial thromboplastin time (aPTT) 
      were used to assess the course of platelet reactivity (PR) and antithrombotic 
      activity. The two groups were similar regarding baseline, angiographic, and 
      interventional characteristics. There was no difference between the two groups in 
      the course of PR following ticagrelor LD. An optimal PR inhibition was obtained 
      4 h after the LD of ticagrelor. The level of antithrombotic activity was 
      significantly lower in the bivalirudin group compared to the UFH group 
      (p < 0.001) during PCI but similar at 2 and 4 h post-PCI. We observed that, in 
      ACS undergoing PCI, the antithrombotic efficacy of an IV bolus of bivalirudin is 
      significantly lower than that of a 70-IU/kg UFH bolus. This could contribute to 
      the excess in thrombotic acute events observed during short-duration PCI.
FAU - Frere, Corinne
AU  - Frere C
AD  - a Service d'hematologie Biologique , Centre hospitalo-universitaire Timone , 
      Marseille , France.
AD  - b Aix-Marseille Universite, INSERM UMR-S 1076 , Vascular Research Center of 
      Marseille , Marseille , France.
FAU - Laine, Marc
AU  - Laine M
AD  - c Service de cardiologie, Centre hospitalo-universitaire , Aix-Marseille 
      universite , Marseille , France.
AD  - d MARS cardio , Mediterraneen Association for research and studies in cardiology 
      , Marseille , France.
FAU - Lemesle, Gilles
AU  - Lemesle G
AD  - e Departement de cardiologie , Centre hospitalo-universitaire de Lille , Lille , 
      France.
FAU - Morange, Pierre-Emmanuel
AU  - Morange PE
AD  - a Service d'hematologie Biologique , Centre hospitalo-universitaire Timone , 
      Marseille , France.
AD  - f Aix-Marseille Universite , INSERM UMR1062, INRA UMR1260, Nutrition, Obesity and 
      Risk of Thrombosis , Marseille , France.
FAU - Paganelli, Franck
AU  - Paganelli F
AD  - c Service de cardiologie, Centre hospitalo-universitaire , Aix-Marseille 
      universite , Marseille , France.
FAU - Dignat-George, Francoise
AU  - Dignat-George F
AD  - b Aix-Marseille Universite, INSERM UMR-S 1076 , Vascular Research Center of 
      Marseille , Marseille , France.
FAU - Resseguier, Noemie
AU  - Resseguier N
AD  - g Aix-Marseille Universite , Department of Biostatistics , Marseille , France.
FAU - Guieu, Regis
AU  - Guieu R
AD  - h Research Unit of Physiology and Pathophysiology in Extreme Oxygenation 
      Conditions (UMR MD2), Faculty of Medicine , Aix-Marseille University , Marseille 
      , France.
FAU - Camoin-Jau, Laurence
AU  - Camoin-Jau L
AD  - a Service d'hematologie Biologique , Centre hospitalo-universitaire Timone , 
      Marseille , France.
FAU - Bonello, Laurent
AU  - Bonello L
AD  - b Aix-Marseille Universite, INSERM UMR-S 1076 , Vascular Research Center of 
      Marseille , Marseille , France.
AD  - c Service de cardiologie, Centre hospitalo-universitaire , Aix-Marseille 
      universite , Marseille , France.
AD  - d MARS cardio , Mediterraneen Association for research and studies in cardiology 
      , Marseille , France.
LA  - eng
PT  - Journal Article
DEP - 20171127
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Hirudins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Recombinant Proteins)
RN  - 9005-49-6 (Heparin)
RN  - TN9BEX005G (bivalirudin)
SB  - IM
MH  - Acute Coronary Syndrome/blood/*complications/metabolism/surgery
MH  - Aged
MH  - Blood Coagulation
MH  - Blood Platelets/drug effects/metabolism
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heparin/*therapeutic use
MH  - Hirudins
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptide Fragments/*therapeutic use
MH  - Percutaneous Coronary Intervention/*adverse effects/methods
MH  - Platelet Aggregation/drug effects
MH  - Recombinant Proteins/therapeutic use
MH  - Risk Factors
MH  - Thrombosis/*etiology/*prevention & control
OTO - NOTNLM
OT  - Acute myocardial infarction
OT  - platelet aggregation
OT  - stent thrombosis
OT  - thrombin
EDAT- 2017/11/28 06:00
MHDA- 2019/03/16 06:00
CRDT- 2017/11/28 06:00
PHST- 2017/11/28 06:00 [pubmed]
PHST- 2019/03/16 06:00 [medline]
PHST- 2017/11/28 06:00 [entrez]
AID - 10.1080/09537104.2017.1384541 [doi]
PST - ppublish
SO  - Platelets. 2019;30(1):105-111. doi: 10.1080/09537104.2017.1384541. Epub 2017 Nov 
      27.